Ribonucleotide reductase inhibitors and future drug design.
about
FBH1 co-operates with MUS81 in inducing DNA double-strand breaks and cell death following replication stressCyclin F-mediated degradation of ribonucleotide reductase M2 controls genome integrity and DNA repairsiRNA Versus miRNA as Therapeutics for Gene SilencingDNA polymerase delta in DNA replication and genome maintenanceThe clinically relevant pharmacogenomic changes in acute myelogenous leukemiaThioredoxin Reductase from Thermoplasma acidophilum : A New Twist on Redox Regulation † , ‡Evaluating the Therapeutic Potential of a Non-Natural Nucleotide That Inhibits Human Ribonucleotide ReductaseThe Cell Killing Mechanisms of HydroxyureaHF-EPR, Raman, UV/VIS light spectroscopic, and DFT studies of the ribonucleotide reductase R2 tyrosyl radical from Epstein-Barr virusAlgorithmic modeling quantifies the complementary contribution of metabolic inhibitions to gemcitabine efficacyA p53 drug response signature identifies prognostic genes in high-risk neuroblastomaMethyl-hydroxylamine as an efficacious antibacterial agent that targets the ribonucleotide reductase enzymePromising cytotoxic activity profile of fermented wheat germ extract (Avemar®) in human cancer cell lines.The conserved Lys-95 charged residue cluster is critical for the homodimerization and enzyme activity of human ribonucleotide reductase small subunit M2In vitro and in vivo efficacy of fluorodeoxycytidine analogs against highly pathogenic avian influenza H5N1, seasonal, and pandemic H1N1 virus infections.Correlating animal and human phase Ia/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA.A phase I study of Triapine in combination with doxorubicin in patients with advanced solid tumors.The maximum tolerated dose and biologic effects of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) in combination with irinotecan for patients with refractory solid tumors.Identifying chelators for metalloprotein inhibitors using a fragment-based approach.Nucleotide metabolism, oncogene-induced senescence and cancer.On model ensemble analyses of nonmonotonic data.Spectroscopic studies of the iron and manganese reconstituted tyrosyl radical in Bacillus cereus ribonucleotide reductase R2 protein.Imexon enhances gemcitabine cytotoxicity by inhibition of ribonucleotide reductase.Phase I study of GTI-2040, an antisense to ribonucleotide reductase, in combination with high-dose cytarabine in patients with acute myeloid leukemia.High expression of ribonucleotide reductase subunit M2 correlates with poor prognosis of hepatocellular carcinoma.Phase I trial of GTI-2040, oxaliplatin, and capecitabine in the treatment of advanced metastatic solid tumors: a California Cancer Consortium Study.A fluorimetric readout reporting the kinetics of nucleotide-induced human ribonucleotide reductase oligomerization.A LC-MS/MS method for the analysis of intracellular nucleoside triphosphate levels.A small-molecule blocking ribonucleotide reductase holoenzyme formation inhibits cancer cell growth and overcomes drug resistanceGene aberrations of RRM1 and RRM2B and outcome of advanced breast cancer after treatment with docetaxel with or without gemcitabine.The expression of ribonucleotide reductase M2 in the carcinogenesis of uterine cervix and its relationship with clinicopathological characteristics and prognosis of cancer patients.A functional approach reveals a genetic and physical interaction between ribonucleotide reductase and CHK1 in mammalian cells.HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle cell lymphomaNovel immunosuppressive agent caerulomycin A exerts its effect by depleting cellular iron contentDetermination of triapine, a ribonucleotide reductase inhibitor, in human plasma by liquid chromatography tandem mass spectrometry.The Novel Ribonucleotide Reductase Inhibitor COH29 Inhibits DNA Repair In VitroIdentification and characterization of genes required for compensatory growth in DrosophilaManagement of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone-induced methemoglobinemia.RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia.Ribonucleotide reductase as one important target of [Tris(1,10-phenanthroline)lanthanum(III)] trithiocyanate (KP772).
P2860
Q24312780-B8810B4E-C148-4B6B-A6C9-428D712D9E4CQ24336569-0020F88C-50EC-416C-B902-C1269D310DB8Q26786876-3C18283C-D929-404C-8756-3360FCD6DEFEQ26991961-9AAB1EFE-F7D9-4013-8249-3BA907BADD0FQ27014790-5F586FA5-A944-4E45-B94E-642004F8B211Q27651732-FF282DE3-AA83-45D5-8508-E9F755C19D59Q27671797-AE55F80B-869C-4FF0-B3F7-33CC8A68E851Q28080250-85C11D73-24E6-495D-BEAC-F8A629C67241Q28477251-16074B63-981D-4C9F-93A3-6723E64F0FF1Q28484288-8C336201-3D61-4462-9A50-F4C9A7B67157Q28537647-C5D6199B-A208-424C-94A1-93093A4B7BACQ28544447-6D07816F-A40C-4646-8BC9-9E9229EBA9C8Q30318418-55F5E3E7-76FB-47DC-9AC0-D65A47F6A850Q30355772-F5F66999-2045-4CB8-B036-0555D6FB2C6AQ30407184-243D7E72-5E99-434C-BACF-4531241AB051Q30837863-2A594988-98F5-4730-9F1A-BFF0C9555FCAQ33382443-24F1198F-61CC-469C-B413-3FBCC8A585C1Q33388089-8E0F34AD-5A90-40AA-B4A7-A2FAC6E15A8BQ33781388-113BFA33-58FF-4B17-A04E-E6C3B51D6C71Q33969333-1D7CF634-6365-4756-AB9D-F33B67EF5E71Q34150280-71D9A029-F4D6-4378-8150-6B9D05D95169Q34202912-2D0FC038-24B6-473E-8F3E-8F17A420514CQ34329957-45444CB9-080B-4953-A96C-6C77584F1416Q34358512-8C6D1282-0275-44FE-9289-96227FEAC7F7Q34432197-FF897870-2E93-49E4-B63C-1E99B1F1AFD7Q34611822-F94AB237-2BAF-401C-A04C-DBC044B413AAQ34740945-3F862FC7-F1D6-4FC9-A33C-59C243812452Q34764487-DD78F4E8-8DB4-4827-9414-A9520A7439D3Q35000541-E2C5B1BD-2E51-414D-9DF1-239FD2129D32Q35038441-FBA2F3B8-9F96-47E9-91DF-BB5077D38428Q35123132-4A370A1E-4411-4372-AF87-1C67F5F0EFF0Q35399015-0EDFD75F-E49B-4857-877F-C086799213CBQ35483623-0A10A606-61AA-4F41-A7DC-12B0A533EBD2Q35484363-84895D3F-8BC3-4FF5-BC49-B2E610BDF35CQ35560319-436E47E6-764F-4FD5-AE42-53756D9FAA66Q35600390-A12A13B2-64BC-4100-A5D4-2FF27E43C911Q35620489-0F4A877B-799F-49E3-8D06-CACA89EDC6E2Q35796011-7DF6EEB8-A2B8-4816-A6B9-47A53E30423DQ36015018-FE8AB99F-B6F1-4500-8930-29083833C550Q36041069-2B246F4B-8A2A-4416-9380-8A27CA9A1DF9
P2860
Ribonucleotide reductase inhibitors and future drug design.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Ribonucleotide reductase inhibitors and future drug design.
@ast
Ribonucleotide reductase inhibitors and future drug design.
@en
type
label
Ribonucleotide reductase inhibitors and future drug design.
@ast
Ribonucleotide reductase inhibitors and future drug design.
@en
prefLabel
Ribonucleotide reductase inhibitors and future drug design.
@ast
Ribonucleotide reductase inhibitors and future drug design.
@en
P2093
P1476
Ribonucleotide reductase inhibitors and future drug design.
@en
P2093
P304
P356
10.2174/156800906777723949
P577
2006-08-01T00:00:00Z